ClinicalTrials.gg
CompletedNCT03901092Updated Sep 9, 2020Results posted

A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation

A Phase 3 interventional study of flortaucipir F 18 in Alzheimer Disease, sponsored by Avid Radiopharmaceuticals. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2020-09-09.

Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
242
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing flortaucipir in Alzheimer Disease — 4 open to participants now, 4 under way, none of them phase 3. flortaucipir · Alzheimer Disease.

Enrollment
3rd of 22
242 · median 70
Started
2019
with 2 others
Phase 3
3 of 22
none open now
Registered
18th of 22
by date
Lead sponsor
15 of 22
Avid Radiopharmaceuticals

Among the 22 studies testing flortaucipir in Alzheimer Disease, this one is the 3rd largest by enrollment, is one of 3 that started in 2019, is one of 3 in phase 3, and was the 18th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

4 of the 22 studies testing flortaucipir in Alzheimer Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About flortaucipir

flortaucipir: first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing flortaucipir in Alzheimer Disease, or all of them as a file.
02

Study summary

This study will evaluate the performance of physician readers trained to read flortaucipir-PET (positron emission tomography) scans.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • flortaucipir F 18
  • Positron Emission Tomography
  • 18F-AV-1451
  • Diagnostic imaging
  • Tau imaging
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Scan Reader Criteria (5 total):

  • Board-certified in radiology or nuclear medicine
  • Professional experience interpreting PET scans
  • Naive to study protocol
  • No previous training or exposure to Avid Flortaucipir F 18 read methodology

Scan Criteria:

  • Previous enrollment in Study A05 confirmatory cohort (NCT02016560), or A16 (NCT02516046)

Scan Study Population Criteria for FR01 (A05 confirmatory cohort):

  • Cognitively-impaired
  • mild cognitive impairment (MCI) or dementia with suspected neurodegenerative cause
  • mini-mental status exam () score of 20-27, inclusive

Scan Study Population Criteria for FR01 (Study A16):

  • Subjects at end of life (less than or equal to 6 months)
  • Imaged with flortaucipir F18 and came to autopsy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
242 participants (actual)

Study arms

  • Experimental
    Flortaucipir PET Scan

    Scans previously acquired from Study A16 (NCT02516046) and A05 (NCT02016560) will be read by independent, blinded readers.

    Drug: flortaucipir F 18

Interventions

  • No study drug will be administered.

    Also known as: 18F-AV-1451, [F-18]T807, LY3191748

06

What researchers measure

Primary outcomes

  1. Primary Objective 1 Analysis 1: Diagnostic Performance of Individual Readers (NFT Score)

    Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem 18F-AV-1451 PET imaging for detection of a pattern of 18F-AV-1451 neocortical uptake that corresponds to neurofibrillary tangles (NFT) Score of B3 (Hyman et al., 2012; Montine et al., 2012). NFT B scores range from B0 (no NFTs in the brain) to B3 (widespread NFTs in the brain). Sensitivity and specificity are percentages that can range from 0 to 100%. The hypothesis tested was that, of the 5 independent imaging physicians, at least 3 will have the lower bounds of 2-sided 95% CIs ≥50%, for both sensitivity and specificity.

    Time frame: baseline scan

  2. Primary Objective 1 Analysis 2: Diagnostic Performance of Individual Readers (NIA-AA Autopsy Diagnosis)

    Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem 18F-AV-1451 PET imaging for detection of a pattern of 18F-AV-1451 neocortical uptake that corresponds to high levels of AD neuropathologic change (High ADNC) as defined by National Institute on Aging-Alzheimer's Association (NIA-AA) criteria (see Hyman et al. 2012). ADNC categories are None, Low, Intermediate and High, with High indicating the most severe level of AD-related pathology changes in the brain. The hypothesis tested was that, of the 5 independent imaging physicians, at least 3 will have the lower bounds of 2-sided 95% CIs ≥50%, for both sensitivity and specificity.

    Time frame: baseline scan

  3. Primary Objective 2: Inter-reader Reliability of Reader Interpretation of Flortaucipir-PET Imaging

    As measured by Fleiss' Kappa across all scans read. Fleiss' kappa is a statistical measure for assessing the reliability of agreement between a fixed number of raters when assigning categorical ratings to a number of items or classifying items. Fleiss' kappa can range from 0 to 1 with 1 indicating perfect agreement between the readers. Scan results binarized as positive AD pattern versus negative AD pattern. Results are displayed as percentage of agreement for individual reader pairs, computed as follows: number of images for which reader had the same interpretation divided by the total number of images evaluated, multiplied by 100%.

    Time frame: baseline scan

Secondary outcomes

  1. Secondary Objective 1 Analysis 1: Diagnostic Performance of τAD++ Flortaucipir PET Images to Detect B3 NFTs

    Flortaucipir F 18 PET imaging will be classified by each reader as either neocortical uptake not consistent with AD (τAD-), neocortical uptake consistent with AD (τAD+), or neocortical uptake consistent with AD with uptake beyond the temporal/occipital regions (τAD++). NFT scoring is according to Hyman, et al 2012. Truth positive is a NFT B3 score. Truth negative is NFT \<B3 score.

    Time frame: baseline scan

  2. Secondary Objective 1 Analysis 2: Diagnostic Performance of τAD++ Flortaucipir PET Images to Detect High ADNC

    Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem 18F-AV-1451 PET imaging for detection of a pattern of 18F-AV-1451 neocortical uptake that corresponds to high levels of AD neuropathologic change (High ADNC) as defined by National Institute on Aging-Alzheimer's Association (NIA-AA) criteria (Hyman et al. 2012). Truth positive is a High ADNC score. Truth negative is No/Low/Intermediate ADNC score.

    Time frame: baseline scan

  3. Secondary Objective 2: Inter-reader Reliability of Reader Interpretation of τAD++ Flortaucipir PET Images

    Overall reader agreement as measured by Fleiss' Kappa statistic. Scan results binarized as τAD++ versus τAD+/τAD-. Results are displayed as percentage of agreement for individual reader pairs, computed as follows: number of images for which reader had the same interpretation divided by the total number of images evaluated, multiplied by 100%.

    Time frame: baseline scan

  4. Secondary Objective 3: Inter-reader Reliability of Flortaucipir PET Scan Interpretation in the Population of Intended Use

    Reader agreement measured by Fleiss' Kappa across scans from non-autopsy cases from Study A05. Scan results binarized as positive for AD pattern versus negative for AD pattern. Results are displayed as percentage of agreement for individual reader pairs, computed as follows: number of images for which reader had the same interpretation divided by the total number of images evaluated, multiplied by 100%.

    Time frame: baseline scan

  5. Secondary Objective 4: Intra-reader Reliability of Reader Interpretation of Flortaucipir-PET Imaging

    Cohen's Kappa will be calculated for each of 5 readers to assess the intra-reader reliability of flortaucipir F 18 PET scan visual interpretation. The statistic takes into account the possibility of the agreement occurring by chance. Cohen's kappa values range from 0 to 1 with 1 representing perfect agreement. Results are displayed as percentage of agreement within a reader, computed as follows: number of images for which reader had the same interpretation at initial and second read divided by the total number of images evaluated twice by a reader, multiplied by 100%.

    Time frame: baseline scan

07

Results

Posted Aug 11, 2020

Participant flow

Subjects were not recruited for this study. Study scans were selected from 2 previously completed imaging studies. Scans previously acquired from Study A16 (NCT02516046) and A05 (NCT02016560) were read by 5 independent, blinded to other study information.

Participant flow — Overall Study
MilestoneAll Autopsy CasesNon-Autopsy Cases
Started83159
Completed83159
Not completed00

Outcome measures

PrimaryPrimary Objective 1 Analysis 1: Diagnostic Performance of Individual Readers (NFT Score)

Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem 18F-AV-1451 PET imaging for detection of a pattern of 18F-AV-1451 neocortical uptake that corresponds to neurofibrillary tangles (NFT) Score of B3 (Hyman et al., 2012; Montine et al., 2012). NFT B scores range from B0 (no NFTs in the brain) to B3 (widespread NFTs in the brain). Sensitivity and specificity are percentages that can range from 0 to 100%. The hypothesis tested was that, of the 5 independent imaging physicians, at least 3 will have the lower bounds of 2-sided 95% CIs ≥50%, for both sensitivity and specificity.

Time frame:
baseline scan
Reported as:
Number · percentage of cases correctly identified
Primary Objective 1 Analysis 1: Diagnostic Performance of Individual Readers (NFT Score)
percentage of cases correctly identifiedSensitivity of Flortaucipir vs Autopsy NFT ScoreSpecificity of Flortaucipir vs Autopsy NFT Score
Reader 191.5 (80.07 to 96.64)77.1 (60.98 to 87.93)
Reader 289.4 (77.41 to 95.37)91.4 (77.62 to 97.04)
Reader 387.2 (74.83 to 94.02)85.7 (70.62 to 93.74)
Reader 493.6 (82.84 to 97.81)62.9 (46.34 to 76.83)
Reader 589.4 (77.41 to 95.37)77.1 (60.98 to 87.93)
PrimaryPrimary Objective 1 Analysis 2: Diagnostic Performance of Individual Readers (NIA-AA Autopsy Diagnosis)

Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem 18F-AV-1451 PET imaging for detection of a pattern of 18F-AV-1451 neocortical uptake that corresponds to high levels of AD neuropathologic change (High ADNC) as defined by National Institute on Aging-Alzheimer's Association (NIA-AA) criteria (see Hyman et al. 2012). ADNC categories are None, Low, Intermediate and High, with High indicating the most severe level of AD-related pathology changes in the brain. The hypothesis tested was that, of the 5 independent imaging physicians, at least 3 will have the lower bounds of 2-sided 95% CIs ≥50%, for both sensitivity and specificity.

Time frame:
baseline scan
Reported as:
Number · percentage of cases correctly identified
Primary Objective 1 Analysis 2: Diagnostic Performance of Individual Readers (NIA-AA Autopsy Diagnosis)
percentage of cases correctly identifiedSensitivity of Flortaucipir vs NIA-AA Autopsy DiagnosisSpecificity of Flortaucipir vs NIA-AA Autopsy Diagnosis
Reader 195.1 (83.86 to 98.65)70.7 (55.52 to 82.39)
Reader 295.1 (83.86 to 98.65)85.4 (71.56 to 93.12)
Reader 395.1 (83.86 to 98.65)82.9 (68.74 to 91.47)
Reader 497.6 (87.40 to 99.57)58.5 (43.37 to 72.24)
Reader 595.1 (83.86 to 98.65)73.2 (58.07 to 84.31)
PrimaryPrimary Objective 2: Inter-reader Reliability of Reader Interpretation of Flortaucipir-PET Imaging

As measured by Fleiss' Kappa across all scans read. Fleiss' kappa is a statistical measure for assessing the reliability of agreement between a fixed number of raters when assigning categorical ratings to a number of items or classifying items. Fleiss' kappa can range from 0 to 1 with 1 indicating perfect agreement between the readers. Scan results binarized as positive AD pattern versus negative AD pattern. Results are displayed as percentage of agreement for individual reader pairs, computed as follows: number of images for which reader had the same interpretation divided by the total number of images evaluated, multiplied by 100%.

Time frame:
baseline scan
Reported as:
Number · percentage agreement of cases
Primary Objective 2: Inter-reader Reliability of Reader Interpretation of Flortaucipir-PET Imaging
percentage agreement of casesAll Cases
Reader 1 v Reader 295.0
Reader 1 v Reader 393.4
Reader 1 v Reader 494.6
Reader 1 v Reader 597.1
Reader 2 v Reader 397.1
Reader 2 v Reader 491.3
Reader 2 v Reader 594.6
Reader 3 v Reader 491.3
Reader 3 v Reader 593.8
Reader 4 v Reader 595.0
Statistical analysis
  • All Cases · Fleiss' kappa: 0.87 · 95% CI 0.83 to 0.91
SecondarySecondary Objective 1 Analysis 1: Diagnostic Performance of τAD++ Flortaucipir PET Images to Detect B3 NFTs

Flortaucipir F 18 PET imaging will be classified by each reader as either neocortical uptake not consistent with AD (τAD-), neocortical uptake consistent with AD (τAD+), or neocortical uptake consistent with AD with uptake beyond the temporal/occipital regions (τAD++). NFT scoring is according to Hyman, et al 2012. Truth positive is a NFT B3 score. Truth negative is NFT \<B3 score.

Time frame:
baseline scan
Reported as:
Number · percentage cases correctly identified
Secondary Objective 1 Analysis 1: Diagnostic Performance of τAD++ Flortaucipir PET Images to Detect B3 NFTs
percentage cases correctly identifiedSensitivity of Flortaucipir tAD++ vs Autopsy NFT ScoreSpecificity of Flortaucipir tAD++ vs Autopsy NFT Score
Reader 187.2 (74.83 to 94.02)88.6 (74.05 to 95.46)
Reader 280.9 (67.46 to 89.58)100.0 (90.11 to 100.00)
Reader 376.6 (62.78 to 86.40)94.3 (81.39 to 98.42)
Reader 489.4 (77.41 to 95.37)82.9 (67.32 to 91.90)
Reader 583.0 (69.86 to 91.11)94.3 (81.39 to 98.42)
SecondarySecondary Objective 1 Analysis 2: Diagnostic Performance of τAD++ Flortaucipir PET Images to Detect High ADNC

Sensitivity and specificity of 5 independent readers' interpretations of ante-mortem 18F-AV-1451 PET imaging for detection of a pattern of 18F-AV-1451 neocortical uptake that corresponds to high levels of AD neuropathologic change (High ADNC) as defined by National Institute on Aging-Alzheimer's Association (NIA-AA) criteria (Hyman et al. 2012). Truth positive is a High ADNC score. Truth negative is No/Low/Intermediate ADNC score.

Time frame:
baseline scan
Reported as:
Number · percentage of cases correctly identified
Secondary Objective 1 Analysis 2: Diagnostic Performance of τAD++ Flortaucipir PET Images to Detect High ADNC
percentage of cases correctly identifiedSensitivitySpecificity
Reader 192.7 (80.57 to 97.48)82.9 (68.74 to 91.47)
Reader 285.4 (71.56 to 93.12)92.7 (80.57 to 97.48)
Reader 385.4 (71.56 to 93.12)92.7 (80.57 to 97.48)
Reader 492.7 (80.57 to 97.48)75.6 (60.66 to 86.17)
Reader 587.8 (74.46 to 94.68)87.8 (74.46 to 94.68)
SecondarySecondary Objective 2: Inter-reader Reliability of Reader Interpretation of τAD++ Flortaucipir PET Images

Overall reader agreement as measured by Fleiss' Kappa statistic. Scan results binarized as τAD++ versus τAD+/τAD-. Results are displayed as percentage of agreement for individual reader pairs, computed as follows: number of images for which reader had the same interpretation divided by the total number of images evaluated, multiplied by 100%.

Time frame:
baseline scan
Reported as:
Number · percentage agreement of cases
Secondary Objective 2: Inter-reader Reliability of Reader Interpretation of τAD++ Flortaucipir PET Images
percentage agreement of casesAll Cases
Reader 1 v Reader 292.5
Reader 1 v Reader 390.0
Reader 1 v Reader 491.3
Reader 1 v Reader 595.0
Reader 2 v Reader 391.7
Reader 2 v Reader 490.5
Reader 2 v Reader 594.2
Reader 3 v Reader 488.8
Reader 3 v Reader 592.5
Reader 4 v Reader 592.9
Statistical analysis
  • All Cases · Fleiss' kappa: 0.84 · 95% CI 0.80 to 0.88
SecondarySecondary Objective 3: Inter-reader Reliability of Flortaucipir PET Scan Interpretation in the Population of Intended Use

Reader agreement measured by Fleiss' Kappa across scans from non-autopsy cases from Study A05. Scan results binarized as positive for AD pattern versus negative for AD pattern. Results are displayed as percentage of agreement for individual reader pairs, computed as follows: number of images for which reader had the same interpretation divided by the total number of images evaluated, multiplied by 100%.

Time frame:
baseline scan
Reported as:
Number · percentage agreement of cases
Secondary Objective 3: Inter-reader Reliability of Flortaucipir PET Scan Interpretation in the Population of Intended Use
percentage agreement of casesA05 Cases
Reader 1 v Reader 297.5
Reader 1 v Reader 393.1
Reader 1 v Reader 495.6
Reader 1 v Reader 597.5
Reader 2 v Reader 393.1
Reader 2 v Reader 494.3
Reader 2 v Reader 596.2
Reader 3 v Reader 493.7
Reader 3 v Reader 593.1
Reader 4 v Reader 596.9
Statistical analysis
  • A05 Cases · Fleiss' kappa: 0.90 · 95% CI 0.85 to 0.95
SecondarySecondary Objective 4: Intra-reader Reliability of Reader Interpretation of Flortaucipir-PET Imaging

Cohen's Kappa will be calculated for each of 5 readers to assess the intra-reader reliability of flortaucipir F 18 PET scan visual interpretation. The statistic takes into account the possibility of the agreement occurring by chance. Cohen's kappa values range from 0 to 1 with 1 representing perfect agreement. Results are displayed as percentage of agreement within a reader, computed as follows: number of images for which reader had the same interpretation at initial and second read divided by the total number of images evaluated twice by a reader, multiplied by 100%.

Time frame:
baseline scan
Reported as:
Number · percentage agreement of cases
Secondary Objective 4: Intra-reader Reliability of Reader Interpretation of Flortaucipir-PET Imaging
percentage agreement of casesRandomly Selected Re-reads
Reader 195.0
Reader 285.0
Reader 380.0
Reader 495.0
Reader 590.0
Statistical analysis
  • Randomly Selected Re-reads · Cohen's kappa: 0.89 · 95% CI 0.69 to 1.00
  • Randomly Selected Re-reads · Cohen's kappa: 0.71 · 95% CI 0.41 to 1.00
  • Randomly Selected Re-reads · Cohen's kappa: 0.60 · 95% CI 0.24 to 0.95
  • Randomly Selected Re-reads · Cohen's kappa: 0.89 · 95% CI 0.67 to 1.00
  • Randomly Selected Re-reads · Cohen's kappa: 0.79 · 95% CI 0.52 to 1.00

Adverse events

Collected over Not applicable. Adverse events were not assessed during this study.. Non-serious events are listed at a 0.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Cases———

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Cases
Study A16 Autopsy Cases81.6 ± 9.91
Study A05 Non-autopsy Cases72.9 ± 9.64
Sex: Female, Male
Sex: Female, Male(Participants)All Cases
Study A16 Autopsy Cases — Female41
Study A16 Autopsy Cases — Male42
Study A05 Non-autopsy Cases — Female74
Study A05 Non-autopsy Cases — Male85
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Cases
Study A16 Autopsy Cases — Hispanic or Latino4
Study A16 Autopsy Cases — Not Hispanic or Latino79
Study A16 Autopsy Cases — Unknown or Not Reported0
Study A05 Non-autopsy Cases — Hispanic or Latino9
Study A05 Non-autopsy Cases — Not Hispanic or Latino150
Study A05 Non-autopsy Cases — Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Cases
Study A16 Autopsy Cases — American Indian or Alaska Native0
Study A16 Autopsy Cases — Asian1
Study A16 Autopsy Cases — Native Hawaiian or Other Pacific Islander0
Study A16 Autopsy Cases — Black or African American1
Study A16 Autopsy Cases — White81
Study A16 Autopsy Cases — More than one race0
Study A16 Autopsy Cases — Unknown or Not Reported0
Study A05 Non-autopsy Cases — American Indian or Alaska Native0
Study A05 Non-autopsy Cases — Asian2
Study A05 Non-autopsy Cases — Native Hawaiian or Other Pacific Islander0
Study A05 Non-autopsy Cases — Black or African American3
Study A05 Non-autopsy Cases — White154
Study A05 Non-autopsy Cases — More than one race0
Study A05 Non-autopsy Cases — Unknown or Not Reported0
08

Study locations

1 site
  • American College of Radiology
    Philadelphia, Pennsylvania 19103, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Apr 2019, 1 month.

Results were first posted in Aug 2020, 1 year 3 months after primary completion. A results delay was requested in Jan 2020.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 1 month is below that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2019
First posted
Apr 3, 2019
StartActual
Mar 26, 2019
Primary completionActual
Apr 26, 2019
CompletionActual
Apr 26, 2019
Results delay requested
Jan 22, 2020
Results first posted
Aug 11, 2020
Last update
Sep 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03901092
Responsible party
Sponsor
First posted
Apr 3, 2019
Start date
Mar 26, 2019
Primary completion
Apr 26, 2019
Completion
Apr 26, 2019
Results posted
Aug 11, 2020
Last update
Sep 9, 2020

Study contacts

Study Director
study director · Avid Radiopharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flortaucipir

Start the discussion